AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION PHASE IB STUDY WITH EXPANSION PHASE TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND THERAPEUTIC ACTIVITY OF EMACTUZUMAB AND RO7009789 ADMINISTERED IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS

Trial Profile

AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION PHASE IB STUDY WITH EXPANSION PHASE TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND THERAPEUTIC ACTIVITY OF EMACTUZUMAB AND RO7009789 ADMINISTERED IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Emactuzumab (Primary) ; RO 7009789 (Primary)
  • Indications Breast cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Mesothelioma; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 06 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top